Bibliography
- Girardi M. Immunosurveillance and immunoregulation by γδ T cells. J Clin Invest Dermatol 2006;126:25-31
- Hayday A, Theodoridis E, Ramsburg E, Shires J. Intraephitelial lymphocytes: exploring the third way in immunology. Nat Immunol 2001;2:997-1003
- Chen ZW, Levtin NL. Vγ9 Vδ2 T cells and anti-microbial immune responses. Microbes Infect 2003;5:491-8
- Bonneville M, Scotet E. Human Vγ9Vδ2 T cells: promising new leads for immunotherapy of infections and tumors. Curr Opin Immunol 2006;5:539-46
- Brandes M., Willimann K, Moser B. Professional Antigen- presentation function by human γδ T cells. Science 2005;309:264-8
- Scotet E, Martinez LO, Grant E, et al. Tumor recognition following Vγ9Vδ2 T cell receptor interactions with a surface F1-ATPase-related structure and apolipoprotein A-I. Immunity 2005;22:71-80
- Constant P, Davodeau F, Peyrat MA, et al. Stimulation of human gamma delta T cells by nonpeptidic mycobacterial ligands. Science 1994;264(5156):267-70
- Hintz M, Reichenberg A, Altincicek B, et al. Identification of (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate as a major activator for human γδ T cells in Escherichia coli. FEBS Lett 2001;509(2):317-22
- Belmant C, Decise D, Fournie´ JJ. Phosphoantigens and aminobisphosphonates: new leads targeting γδ T lymphocytes for cancer immunotherapy. Drug Discov Today Ther Strateg 2006;3(1):17-23
- Tanaka Y, Sano S, Nieves E, et al. Nonpeptide ligands for human γδ T cells. Proc Natl Acad Sci USA 1994;91(17):8175-9
- Belmant C, Espinosa E, Halary F, et al. A chemical basis for selective recognition of nonpeptide antigens by human γδ T cells. FASEB J 2000;14:1669-70
- Espinosa E, Belmant C, Pont F, et al. Chemical synthesis and biological activity of bromohydrin pyrophosphate, a potent stimulator of human γδ T cells. J Biol Chem 2001;276:18337-44
- Song Y, Zhang Y, Wang H, et al. Synthesis of chiral phosphoantigens and their activity in γδ T cell stimulation. Bioorg Med Chem Lett 2004;14:4471-7
- Morita CT, Beckman EM, Bukowski JF, et al. Direct presentation of non peptide prenyl pyrophosphate antigens to human γδ T cells. Immunity 1995;3:495-507
- Morita CT, Chenggang J, Ghanashyam S, Hong Wang. Non peptide antigens, presentation mechanisms, and immunological memory of human Vγ9 Vδ2T cells: discriminating friend from foe through the recognition of prenyl pyrophosphate antigens. Immunol Rev 2007;215:59-76
- Parker CM, Groh V, Band H, et al. Evidence for extrathymic changes in the T cell receptor γ/δ repertoire. J Exp Med 1990;171:1597-612
- Morita CT, Parker CM, Brenner MB, Band H. T cell receptor usage and functional capabilities of human γδ T cells at birth. J Immunol 1994;153:3979-88
- Dieli F, Poccia F, Lipp M, et al. Differentiation of effector/memory Vδ2 T cells and migratory routes in lymph nodes or inflammatory sites. J Exp Med 2003;198:391-7
- Angelini DF, Borsellino G, Poupot M, et al. FcγRIII discriminates between 2 subsets of Vγ9Vδ2 effector cells with different responses and activation pathways. Blood 2004;104:1801-7
- Caccamo N, Meraviglia S, Ferlazzo V, et al. Differential requirements for antigen or homeostatic cytokines for proliferation and differentiation of human Vγ9Vδ2 naive, memory and effector T cell subsets. Eur J Immunol 2005;35:1764-72
- Shen Y, Zhou D, Qiu L, et al. Adaptive immune response of Vγ9 Vδ2 T cells during mycobacterial infections. Science 2002;295:2255-8
- Lai X, Shen Y, Zhou D, et al. Immune biology of macaque lymphocyte populations during mycobacterial infection. Clin Exp Immunol 2003;133:182-92
- Cendron D, Ingoure S, Martino A, et al. A tuberculosis vaccine based on phosphoantigens and fusion proteins induces distinct γδ and αβ T cell responses in primates. Eur J Immunol 2007;37:549-65
- Dieli F, Sireci G, Di Sano C, et al. Ligand-specific αβ and γδ T cell responses in childhood tuberculosis. Infect Dis 2000;181:294-301
- Galluzzo S, Santini D, Vincenzi B, et al. Immunomodulating role of bisphosphonates on human gamma delta T cells: an intriguing and promising aspect of their antitumor activity. Expert Opin Ther Targets 2007;11(7):941-54
- Clézardin P. The antitumor potential of bisphosphonates. Semin Oncol 2002;29:33-42
- Coleman RE. Bisphosphonates: clinical experience. Oncologist 2004;9:14-27
- Kunzmann V, Bauer E, Wilhelm M. Gamma delta T-cell stimulation by pamidronate. N Engl J Med 1999;340:737-8
- Kohno N, Aogi K, Minami H, et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 2005;23:3314-21
- Lipton A, Zheng M, Seaman J. Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma. Cancer 2003;98:962-9
- Saad F, Gleason DM, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone refractory prostate cancer. J Natl Cancer Inst 2004;96:879-82
- Gober HJ, Kistowska M, Angman L, et al. Human T cell receptor γδ cells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med 2003;197:163-8
- Ferlazzo V, Sferrazza C, Caccamo N, et al. In vitro effects of aminobisphosphonates on Vgamma9 Vdelta2 T cell activation and differentiation. Int J Immunopathol Pharmacol 2006;19:309-17
- Roelofs AJ, Thompson K, Gordon S, Rogers MJ. Molecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res 2006;12:6222s-6230s
- Lipton A, Theriault RL, Hortobagyi GN, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 2000;88:1082-90
- Kunzmann V, Bauer E, Feurle J, et al. Stimulation of γδ T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 2000;96:384-92
- Wilhelm M, Kunzmann V, Eckstein S, et al. γδ T cells for immune therapy of patients with lymphoid malignancies. Blood 2003;102:200-6
- Dieli F, Gebbia N, Poccia F, et al. Induction of γδ T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo. Blood 2003;102:2310-1
- Vermijlen D, Ellis P, Langford C, et al. Distinct cytokine-driven responses of activated blood γδ T cells: insights into unconventional T cell pleiotropy. J Immunol 2007;178:4304-14
- Wesch D, Glatzel A, Kabelitz D. Differentiation of resting human peripheral blood γδ T cells toward Th1- or Th2-phenotype. Cell Immunol 2001;212:110-7
- Eberl M, Engel R, Beck E, Jomaa H. Differentiation of human γδ T cells towards distinct memory phenotypes. Cell Immunol 2002;218:1-6
- Dieli F, Vermijlen D, Fulfaro F, et al. Targeting human γδ T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res 2007;67(15):7450-7
- Kobayashi H, Tanaka Y, Yagi J, et al. Safety profile and anti-tumor effects of adoptive immunotherapy using gamma-delta T cells against advanced renal cell carcinoma: a pilot study. Cancer Immunol Immunother 2007;56:469
- Bennouna J, Bompas E, Neidhardt EM, et al. Phase-I study of Innacell γδ™, an autologous cell-therapy product highly enriched in γ9δ2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma. Cancer Immunol Immunother 2008: published online 27 Feb 2008, doi:10.1007/s00262-008-0491-8
- Casetti R, Perretta G, Taglioni A, et al. Drug-induced expansion and differentiation of Vγ9Vδ2 T cells in vivo: the role of exogenous IL-2. J Immunol 2005;175:1593-8
- Ali Z, Shao L, Halliday L, Reichenberg A, et al. Prolonged (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate-driven antimicrobial and cytotoxic responses of pulmonary and systemic Vγ2Vδ2 T cells in macaques. J Immunol 2007;179:8287-96
- Sicard H, Ingoure S, Luciani B, et al. In vivo immunomanipulation of Vγ9Vδ2 T cells with a synthetic phosphoantigen in a preclinical nonhuman primate model. J Immunol 2005;175:5471-80
- Kabelitz D, Wesch D, Pitters E, Zöller M. Characterization of tumor reactivity of human Vγ9Vδ2 γδ T cells in vitro and in SCID mice in vivo. J Immunol 2004;173:6767-76
- Yang JC, Sherry RM, Steinberg SM, et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 2003;15:3127-32
- FDA approves ZOMETA for treatment of cancer-related bone complications. Expert Rev Anticancer Ther 2002;2:137-8